[HTML][HTML] Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review

WK Chan, KH Chuah, RB Rajaram, LL Lim… - Journal of obesity & …, 2023 - ncbi.nlm.nih.gov
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for
steatotic liver disease associated with metabolic syndrome. MASLD is the most common …

[HTML][HTML] Steatotic liver disease: metabolic dysfunction, alcohol, or both?

K Staufer, RE Stauber - Biomedicines, 2023 - mdpi.com
Non-alcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD), both of
them accounting for fatty liver disease (FLD), are among the most common chronic liver …

MetALD: new opportunities to understand the role of alcohol in steatotic liver disease

M Israelsen, N Torp, S Johansen, M Thiele… - The Lancet …, 2023 - thelancet.com
For many years non-alcoholic fatty liver disease (NAFLD) and alcohol-related liver disease
(ALD) have been considered as two biologically and clinically distinct conditions. According …

Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease

H Lin, HW Lee, TCF Yip, E Tsochatzis, S Petta… - Jama, 2024 - jamanetwork.com
Importance Metabolic dysfunction–associated steatotic liver disease (MASLD) is currently
the most common chronic liver disease worldwide. It is important to develop noninvasive …

Long‐term follow‐up of web‐based and group‐based behavioural intervention in NAFLD in a real world clinical setting

ML Petroni, S Colosimo, L Brodosi… - Alimentary …, 2024 - Wiley Online Library
Background The long‐term results of web‐based behavioural intervention in non‐alcoholic
fatty liver disease (NAFLD) have not been described in patients followed in specialised …

[HTML][HTML] Making Sense of the Nonalcoholic Fatty Liver Disease Clinical Practice Guidelines: What Clinicians Need to Know

K Cusi, J Budd, E Johnson, J Shubrook - Diabetes Spectrum, 2024 - Am Diabetes Assoc
Standards of care summarized in clinical practice guidelines for nonalcoholic fatty liver
disease (NAFLD) offer clinicians a streamlined diagnostic and management approach …

[HTML][HTML] Long-term major adverse liver outcomes in 1,260 patients with non-cirrhotic NAFLD

C Akbari, M Dodd, P Stål, P Nasr, M Ekstedt… - JHEP Reports, 2024 - Elsevier
Background & Aims Long-term studies of the prognosis of NAFLD are scarce. Here, we
investigated the risk of major adverse liver outcomes (MALO) in a large cohort of patients …

[HTML][HTML] WFUMB guidelines/guidance on liver multiparametric ultrasound. Part 2: guidance on liver fat quantification

G Ferraioli, RG Barr, A Berzigotti, I Sporea… - Ultrasound in medicine …, 2024 - Elsevier
Abstract The World Federation for Ultrasound in Medicine and Biology (WFUMB) has
promoted the development of this document on multiparametric ultrasound. Part 2 is a …

Short‐term reduction of dietary gluten improves metabolic‐dysfunction associated steatotic liver disease: a randomised, controlled proof‐of‐concept study

A Armandi, H Bespaljko, A Mang… - Alimentary …, 2024 - Wiley Online Library
Background The current management of metabolic dysfunction‐associated steatotic liver
disease (MASLD) relies on lifestyle intervention. Prior studies have shown that nutritional …

[HTML][HTML] Role of insulin resistance in the development of nonalcoholic fatty liver disease in people with type 2 diabetes: from bench to patient care

JP Nogueira, K Cusi - Diabetes Spectrum, 2024 - Am Diabetes Assoc
Insulin resistance is implicated in both the pathogenesis of nonalcoholic fatty liver disease
(NAFLD) and its progression from steatosis to steatohepatitis, cirrhosis, and even …